Last reviewed · How we verify
Kenalog (triamcinolone)
Triamcinolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.
Triamcinolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors. Used for Inflammatory and allergic conditions (e.g., rheumatoid arthritis, lupus, asthma), Dermatological conditions (e.g., eczema, psoriasis, lichen planus), Endocrine disorders (e.g., adrenocortical insufficiency).
At a glance
| Generic name | Kenalog (triamcinolone) |
|---|---|
| Also known as | Steriod, Corticosteroid |
| Sponsor | Walter Reed National Military Medical Center |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Dermatology, Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Triamcinolone acts as a glucocorticoid receptor agonist, entering cells and binding to intracellular glucocorticoid receptors. This leads to suppression of pro-inflammatory cytokine production, inhibition of immune cell activation and migration, and stabilization of lysosomal membranes. These effects reduce inflammation and immune-mediated tissue damage across multiple organ systems.
Approved indications
- Inflammatory and allergic conditions (e.g., rheumatoid arthritis, lupus, asthma)
- Dermatological conditions (e.g., eczema, psoriasis, lichen planus)
- Endocrine disorders (e.g., adrenocortical insufficiency)
- Hematologic conditions (e.g., thrombocytopenia, hemolytic anemia)
- Ophthalmic inflammation
Common side effects
- Immunosuppression / increased infection risk
- Hyperglycemia / glucose intolerance
- Hypertension
- Osteoporosis / bone loss
- Cushingoid features (with chronic use)
- Adrenal suppression
- Insomnia / mood changes
- Gastrointestinal upset
Key clinical trials
- Dose Dependent Steroid Injections (PHASE4)
- A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome (PHASE4)
- Sialendoscopy Versus Photobiomodulation in Prevention of Radiation Induced Xerostomia (NA)
- Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone (PHASE4)
- USG-Guided Shoulder Injections in Frozen Shoulder (NA)
- Local Methotrexate Injections for the Treatment of Nail Psoriasis (PHASE4)
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kenalog (triamcinolone) CI brief — competitive landscape report
- Kenalog (triamcinolone) updates RSS · CI watch RSS
- Walter Reed National Military Medical Center portfolio CI